Drug Profile
SPX 101
Alternative Names: SPX-101Latest Information Update: 25 Jul 2022
Price :
$50
*
At a glance
- Originator Spyryx Biosciences
- Class Antifibrotics; Peptides
- Mechanism of Action Epithelial sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cystic fibrosis
Most Recent Events
- 25 Jul 2022 No development reported - Phase-II for Cystic fibrosis in Canada (Inhalation)
- 25 Jul 2022 No development reported - Phase-II for Cystic fibrosis in France (Inhalation)
- 25 Jul 2022 No development reported - Phase-II for Cystic fibrosis in Italy (Inhalation)